Phase II study of the efficacy and safety of lenvatinib for anaplastic thyroid cancer (HOPE)
Takuya Higashiyama, Kiminori Sugino, Hisato Hara, Ken‐ichi Ito, Noriaki Nakashima, Naoyoshi Onoda, Masayuki Tori, Hiroshi Katoh, Naomi Kiyota, Ichiro Ota, Nobuyasu Suganuma, Yatsuka Hibi, Toshimitsu Nemoto, Shunji Takahashi, Katsunari Yane, Tetsuya Ioji, Shinsuke Kojima, Hideaki Kaneda, Iwao Sugitani, Makoto Tahara
Topics & Concepts
MedicineLenvatinibInternal medicineAnaplastic thyroid cancerAdverse effectThyroid cancerClinical endpointPhases of clinical researchCancerOncologySurgeryClinical trialGastroenterologyThyroid Cancer Diagnosis and TreatmentCancer, Lipids, and MetabolismThyroid and Parathyroid Surgery